Second, SGLT2 inhibitors which have been developed to lower blood glucose levels in Type 2 diabetes mellitus may have a therapeutic potential for astrocytomas [2]. This evidence concerns the gene SLC5A2 and astrocytoma (excluding glioblastoma).